Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 4/2012

01-11-2012

Thromboprophylaxis in major knee and hip replacement surgery: a review

Authors: Gonzalo Eymin, Amir K. Jaffer

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2012

Login to get access

Abstract

Patients undergoing total knee and total hip replacement (THR/TKR) surgery are at high risk of venous thromboembolism (VTE), and routine thromboprophylaxis is recommended after these procedures. However, current thromboprophylaxis may require daily injections, careful anticoagulation monitoring, and dietary restrictions, which can lead to poor patient compliance and suboptimal outcomes. Therefore, there is an unmet need for simpler medication options. Newer oral anticoagulants have improved efficacy over standard treatments, with convenient dosing regimens, more predictable pharmacologic profiles that reduce the need for anticoagulation monitoring, and fewer drug or food interactions. These drugs have the potential to simplify anticoagulation after THR or TKR surgery, which may lead to improved adherence, thus lowering the incidence of VTE and associated complications after surgery.
Literature
1.
FalckYtter Y, Francis CW, Johanson NA et al (2012) Prevention of VTE in orthopedic surgery patients-antithrombotic therapy and prevention of thrombosis, 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2):e279S–e325SCrossRef
2.
Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edn. Chest 133:381S–453SPubMedCrossRef
3.
Spyropoulos AC, Anderson FA Jr, Fitzgerald G et al (2011) Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 140:706–714PubMedCrossRef
4.
Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ (2009) Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost 102:688–693PubMed
5.
White RH, Henderson MC (2002) Risk factors for venous thromboembolism after total hip and knee replacement surgery. Curr Opin Pulm Med 8:365–371PubMedCrossRef
6.
Chin PL, Amin MS, Yang KY et al (2009) Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial. J Orthop Surg (Hong Kong) 17:1–5
7.
Yokote R, Matsubara M, Hirasawa N et al (2011) Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population? J Bone Joint Surg Br 93:251–256PubMedCrossRef
8.
Cohen AT, Skinner JA, Warwick D, Brenkel I (2007) The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study. J Bone Joint Surg Br 89:887–892PubMedCrossRef
9.
Edwards JZ, Pulido PA, Ezzet KA et al (2008) Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty. J Arthroplasty 23:1122–1127PubMedCrossRef
10.
Silbersack Y, Taute BM, Hein W, Podhaisky H (2004) Prevention of deep-vein thrombosis after total hip and knee replacement. Low-molecular-weight heparin in combination with intermittent pneumatic compression. J Bone Joint Surg Br 86:809–812PubMedCrossRef
11.
Arepally GM, Ortel TL (2006) Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355:809–817PubMedCrossRef
12.
Al Rossaies A, Alkharfy KM, Al Ayoubi F, Al Momen A (2011) Heparin-induced thrombocytopenia: comparison between response to fondaparinux and lepirudin. Int J Clin Pharm 33:997–1001PubMedCrossRef
13.
Friedman RJ, Gallus AS, Cushner FD et al (2008) Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 24:87–97PubMed
14.
Deitelzweig SB, Lin J, Kreilick C et al (2010) Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther 27:623–633PubMedCrossRef
15.
van Walraven C, Jennings A, Oake N et al (2006) Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 129:1155–1166PubMedCrossRef
16.
Ansell J, Hollowell J, Pengo V et al (2007) Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the International Study of Anticoagulation Management (ISAM). J Thromb Thrombolysis 23:83–91PubMedCrossRef
17.
Rose AJ, Ozonoff A, Grant RW et al (2009) Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2:591–597PubMedCrossRef
18.
Begelman SM, Hursting MJ, Aghababian RV, McCollum D (2005) Heparin-induced thrombocytopenia from venous thromboembolism treatment. J Intern Med 258:563–572PubMedCrossRef
19.
Smythe MA, Warkentin TE, Stephens JL et al (2002) Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 71:50–52PubMedCrossRef
20.
21.
Al Rossaies A, Alkharfy KM, Al Ayoubi F, Al Momen A (2011) Heparin-induced thrombocytopenia: comparison between response to fondaparinux and lepirudin. Int J Clin Pharm 33:997–1001PubMedCrossRef
22.
Eriksson BI, Wille-Jorgensen P, Kalebo P et al (1997) A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 337:1329–1335PubMedCrossRef
23.
Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162:1833–1840PubMedCrossRef
24.
25.
Streiff MB, Haut ER (2009) The CMS ruling on venous thromboembolism after total knee or hip arthroplasty: weighing risks and benefits. JAMA 301:1063–1065PubMedCrossRef
26.
Friedman RJ, Dahl OE, Rosencher N et al (2010) Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 126:175–182PubMedCrossRef
27.
Stangier J, Clemens A (2009) Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 15(Suppl 1):9S–16SPubMedCrossRef
28.
Eriksson BI, Quinlan DJ, Weitz JI (2009) Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 48:1–22PubMedCrossRef
29.
Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949–956PubMedCrossRef
30.
Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765–2775PubMedCrossRef
31.
Eriksson BI, Dahl OE, Rosencher N et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178–2185PubMedCrossRef
32.
Ginsberg JS, Davidson BL, Comp PC et al (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24:1–9PubMed
33.
Kakkar AK, Brenner B, Dahl OE et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31–39PubMedCrossRef
34.
Lassen MR, Ageno W, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776–2786PubMedCrossRef
35.
Lassen MR, Raskob GE, Gallus A et al (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361:594–604PubMedCrossRef
36.
Lassen MR, Raskob GE, Gallus A et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807–815PubMedCrossRef
37.
Lassen MR, Gallus A, Raskob GE et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363:2487–2498PubMedCrossRef
38.
Turpie AG, Lassen MR, Davidson BL et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673–1680PubMedCrossRef
39.
Romualdi E, Ageno W (2010) Oral Xa inhibitors. Hematol Oncol Clin North Am 24:727–737
40.
Turpie AG, Lassen MR, Eriksson BI et al (2011) Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Thromb Haemost 105(3):444–453PubMedCrossRef
41.
Dahl OE, Quinlan DJ, Bergqvist D et al (2010) A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost 8(9):1966–1975PubMedCrossRef
42.
Raskob GE, Gallus AS, Pineo GF et al (2012) Apixaban versus enoxaparin for thromboprophlaxis after hip or knee replacement. J Bone Joint Surg Br 94(2):257–264PubMedCrossRef
Metadata
Title
Thromboprophylaxis in major knee and hip replacement surgery: a review
Authors
Gonzalo Eymin
Amir K. Jaffer
Publication date
01-11-2012
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2012
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-012-0751-5

Other articles of this Issue 4/2012

Journal of Thrombosis and Thrombolysis 4/2012 Go to the issue

OriginalPaper

Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention

OriginalPaper

Plasma accumulation of fondaparinux 2.5 mg in patients after total hip arthroplasty

Letter to the Editor

Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin

Letter to the Editor

How to prevent bleeding events in on- and off-pump coronary artery bypass patients exposed to clopidogrel preoperatively

OriginalPaper

Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up

OriginalPaper

Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels predict percutaneous coronary intervention-related periprocedural myocardial infarction in stable patients undergoing elective native single-vessel PCI
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits